Osteopenia and osteoporosis in young men presenting with infertility or sexual dysfunction - clinical experience

1. Gennari L, Bilezikian JP. Osteoporosis in men: pathophysiology and treatment. Curr Rheumatol Rep 2007; 9: 71–77.

2. Melton LJ, 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005–1010.

3. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin North Am 2007; 36: 399 –419.

4. Cooper C, Campion G, Melton LJ, 3rd Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285–289.

5. Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E. Bone fragility in men–where are we? Osteoporos Int 2006; 17: 1577–1583.

6. Abbasi AA, Rudman D, Wilson CR, Drinka PJ, Basu SN, Mattson DE, Richardson TJ. Observations on nursing home residents with a history of hip fracture. Am J Med Sci 1995; 310: 229–234.

7. Allain TJ. Prostate cancer, osteoporosis and fracture risk. Gerontology 2006; 52: 107–110.

8. McLeod N, Huynh CC, Rashid P. Osteoporosis from androgen deprivation therapy in prostate cancer treatment. Aust Fam Physician 2006; 35: 243–245.

9. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D. Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 2001; 69: 218–221.

10. Looker AC, Orwoll ES, Johnston CC Jr., Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12: 1761–1768.

11. Melton LJ. 3rd The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 2001; 69: 179–181.

12. Marshall LM, Zmuda JM, Chan BK, Barrett-Connor E, Cauley JA, Ensrud KE, Lang TF, Orwoll ES. Race and ethnic variation in proximal femur structure and BMD among older men. J Bone Miner Res 2008; 23: 121–130.

13. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S–19S.

14. Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999; 10: 73–78.

15. Becker C. Pathophysiology and clinical manifestations of osteoporosis. Clin Cornerstone 2006; 8: 19–27.

16. Smith EL, Raab DM. Osteoporosis and physical activity. Acta Med Scand Suppl 1986; 711: 149–156.

17. Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996; 59 Suppl 1: S2–9.

18. You L, Temiyasathit S, Lee P, Kim CH, Tummala P, Yao W, Kingery W, Malone AM, Kwon RY, Jacobs CR. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone 2008; 42: 172–179.

19. Silvestrini G, Ballanti P, Sebastiani M, Leopizzi M, Di Vito M, Bonucci E. OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST. J Mol Histol 2008; 39: 237–242.

20. Kaji H, Sugimoto T, Kanatani M, Nasu M, Chihara K. Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathway. Endocrinology 1996; 137: 2217–2224.

21. Lau KH, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65: 295–306.

22. Jayasinghe Y, Grover SR, Zacharin M. Current concepts in bone and reproductive health in adolescents with anorexia nervosa. BJOG 2008; 115: 304–315.

23. Cooper C, Harvey N, Javaid K, Hanson M, Dennison E. Growth and bone development. Nestle Nutr Workshop Ser Pediatr Program 2008; 61: 53–68.

24. Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Drugs Aging 1998; 13: 421–434.

25. Yialamas MA, Hayes FJ. Androgens and the ageing male and female. Best Pract Res Clin Endocrinol Metab 2003; 17: 223–236.

26. Samelson EJ, Hannan MT. Epidemiology of osteoporosis. Curr Rheumatol Rep 2006; 8: 76–83.

27. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005; 12: 1071–1082.

28. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004; 25: 389–425.

29. Krassas GE, Papadopoulou P. Oestrogen action on bone cells. J Musculoskelet Neuronal Interact 2001; 2: 143–151.

30. Chowdhury S, Pickering LM, Ellis PA. Adjuvant aromatase inhibitors and bone health. J Br Menopause Soc 2006; 12: 97–103.

31. Carreau S. Estrogens–male hormones? Folia Histochem Cytobiol 2003; 41: 107–111.

32. Bulun SE. Aromatase deficiency and estrogen resistance: from molecular genetics to clinic. Semin Reprod Med 2000; 18: 31–39.

33. Jones ME, Boon WC, Proietto J, Simpson ER. Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol Metab 2006; 17: 55–64.

34. Wang Q, Alen M, Nicholson PH, Halleen JM, Alatalo SL, Ohlsson C, Suominen H, Cheng S. Differential effects of sex hormones on peri- and endocortical bone surfaces in pubertal girls. J Clin Endocrinol Metab 2006; 91: 277–282.

35. Frank GR. Role of estrogen and androgen in pubertal skeletal physiology. Med Pediatr Oncol 2003; 41: 217–221.

36. Martel C, Melner MH, Gagne D, Simard J, Labrie F. Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 1994; 104: 103–111.

37. Blanchard PG, Luu-The V. Differential androgen and estrogen substrates specificity in the mouse and primates type 12 17beta-hydroxysteroid dehydrogenase. J Endocrinol 2007; 194: 449–455.

38. Yanase T, Suzuki S, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H. Aromatase in bone: roles of Vitamin D3 and androgens. J Steroid Biochem Mol Biol 2003; 86: 393–397.

39. Janssen JM, Bland R, Hewison M, Coughtrie MW, Sharp S, Arts J, Pols HA, van Leeuwen JP. Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J Cell Biochem 1999; 75: 528–537.

40. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, Bovee JV, Karperien M, Hogendoorn PC. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005; 11: 8028–8035.

41. Venken K, Schuit F, Van Lommel L, Tsukamoto K, Kopchick JJ, Coschigano K, Ohlsson C, Moverare S, Boonen S, Bouillon R, Vanderschueren D. Growth without growth hormone receptor: estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis. J Bone Miner Res 2005; 20: 2138– 2149.

42. Savendahl L. Hormonal regulation of growth plate cartilage. Horm Res 2005; 64 Suppl 2: 94–97.

43. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008; 27: 535–545.

44. Vanderschueren D, Gaytant J, Boonen S, Venken K. Androgens and bone. Curr Opin Endocrinol Diabetes Obes 2008 ;15: 250–254.

45. Kasperk CH, Wakley GK, Hierl T, Ziegler R. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 1997; 12: 464–471.

46. Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Nasu M, Chihara K. Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone. J Cell Physiol 1997; 172: 55–62.

47. Wang Y, Nishida S, Boudignon BM, Burghardt A, Elalieh HZ, Hamilton MM, Majumdar S, Halloran BP, Clemens TL, Bikle DD. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 2007; 22: 1329–1337.

48. Niu T, Rosen CJ. The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene 2005; 361: 38–56.

49. Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005; 20: 2224–2232.

50. Vanderschueren D, Van Herck E, Schot P, Rush E, Einhorn T, Geusens P, Bouillon R. The aged male rat as a model for human osteoporosis: evaluation by nondestructive measurements and biomechanical testing. Calcif Tissue Int 1993; 53: 342–347.

51. Vanderschueren D, Van Herck E, De Coster R, Bouillon R. Aromatization of androgens is important for skeletal maintenance of aged male rats. Calcif Tissue Int 1996; 59: 179–183.

52. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007; 99: 350–356.

53. Jochems C, Islander U, Kallkopf A, Lagerquist M, Ohlsson C, Carlsten H. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis Rheum 2007; 56: 3261–3270.

54. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, Holmberg A, Redlund-Johnell I, Orwoll E, Ohlsson C. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21: 529–535.

55. Rapado A, Hawkins F, Sobrinho L, Diaz-Curiel M, Galvao-Telles A, Arver S, Melo Gomes J, Mazer N, Garcia e Costa J, Horcajada C, Lopez-Gavilanes E, Mascarenhas M, Papapietro K, Lopez Alvarez MB, Pereira MC, Martinez G, Valverde I, Garcia JJ, Carballal JJ, Garcia I. Bone mineral density and androgen levels in elderly males. Calcif Tissue Int 1999; 65: 417–421.

56. Diver MJ. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Ann Clin Biochem 2006; 43: 3–12.

57. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405–413.

58. Bay K, Andersson AM, Skakkebaek NE. Estradiol levels in prepubertal boys and girls–analytical challenges. Int J Androl 2004; 27: 266–273.

59. Kushnir MM, Rockwood AL, Roberts WL, Pattison EG, Bunker AM, Fitzgerald RL, Meikle AW. Performance characteristics of a novel tandem mass spectrometry assay for serum testosterone. Clin Chem 2006; 52: 120–128.

60. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007; 21: 109–122.

61. Lane NE. An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 2001; 27: 235–253.

62. Turner RT. Skeletal response to alcohol. Alcohol Clin Exp Res 2000; 24: 1693–1701.

63. Yuan Z, Dawson N, Cooper GS, Einstadter D, Cebul R, Rimm AA. Effects of alcohol-related disease on hip fracture and mortality: a retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health 2001; 91: 1089–1093.

64. Adler RA. Epidemiology and pathophysiology of osteoporosis in men. Curr Osteoporos Rep 2006; 4: 110–115.

65. Perry HM, 3rd, Morley JE. Osteoporosis in men: are we ready to diagnose and treat? Curr Rheumatol Rep 2001; 3: 240–244.

66. Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone K. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study–a large observational study of the determinants of fracture in older men. Contemp Clin Trials 2005; 26: 569–585.

67. Placide J, Martens MG. Comparing screening methods for osteoporosis. Curr Womens Health Rep 2003; 3: 207–210.

68. Hochberg MC. Recommendations for measurement of bone mineral density and identifying persons to be treated for osteoporosis. Rheum Dis Clin North Am 2006; 32: 681–689.

69. Bauer DC, Ewing SK, Cauley JA, Ensrud KE, Cummings SR, Orwoll ES. Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study. Osteoporos Int 2007; 18: 771–777.

70. Orwoll E. Assessing bone density in men. J Bone Miner Res 2000; 15: 1867–1870.

71. Allende-Vigo MZ. The use of biochemical markers of bone turnover in osteoporosis. P R Health Sci J 2007; 26: 91–95.

72. Rochira V, Balestrieri A, Madeo B, Zirilli L, Granata AR, Carani C. Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho) physiology. Eur J Endocrinol 2006; 154: 175–185.

73. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58: 101–107.

74. Francis RM. The effects of testosterone on osteoporosis in men. Clin Endocrinol (Oxf) 1999; 50: 411– 414.

75. Kamel HK. Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 2005; 22: 741–748.

76. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386–2390.

77. Scott JD, Wolfe PR, Anderson P, Cohan GR, Scarsella A. Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. HIV Clin Trials 2007; 8: 412–420.

78. Fabbri A, Giannetta E, Lenzi A, Isidori AM. Testosterone treatment to mimic hormone physiology in androgen replacement therapy. A view on testosterone gel and other preparations available. Expert Opin Biol Ther 2007; 7: 1093–1106.

79. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358–4365.

80. Guo CY, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 1997; 82: 658–665.

81. Horowitz M, Wishart JM, O'Loughlin PD, Morris HA, Need AG, Nordin BE. Osteoporosis and Klinefelter's syndrome. Clin Endocrinol (Oxf) 1992; 36: 113–118.

82. van den Bergh JP, Hermus AR, Spruyt AI, Sweep CG, Corstens FH, Smals AG. Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution. Osteoporos Int 2001; 12: 55–62.

83. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098.

84. von Muhlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int 2008; 19: 699–707.

85. Lunenfeld B. Androgen therapy in the aging male. World J Urol 2003; 21: 292–305.

86. Kenny AM, Prestwood KM. Osteoporosis. Pathogenesis, diagnosis, and treatment in older adults. Rheum Dis Clin North Am 2000; 26: 569–591.

87. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006; 12: 6315s–6319s.

88. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148: 197–213.

89. Malozowski S. Treatment of adolescents with gynecomastia. J Pediatr 2005; 146: 576; author reply 576–577.

90. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004; 145: 71–76.

91. Kastelan D, Giljevic Z, Kraljevic I, Korsic M. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males. Med Hypotheses 2006; 67: 1052–1053.

92. Smith MR. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology (Williston Park) 2004; 18: 21–25.

93. Bell NH, Johnson RH. Bisphosphonates in the treatment of osteoporosis. Endocrine 1997; 6: 203–206.

94. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 1989; 116: 1–28.

95. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007; 119 Suppl 2: S150– 162.

96. Valverde P. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem 2008; 15: 284–304.

97. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008.

98. Hochberg MC, Rizzoli R. Long-term experience with alendronate in the treatment of osteoporosis. Expert Opin Pharmacother 2006; 7: 1201–1210.

99. Tuck SP, Datta HK. Osteoporosis in the aging male: treatment options. Clin Interv Aging 2007; 2: 521–536.

100. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005; 64: 176–178.

101. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047–1053.

102. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548–1558.

103. Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, Cortet B. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2008; 75: 34–40.

104. Agnusdei D, Gentilella R. GH and IGF-I as therapeutic agents for osteoporosis. J Endocrinol Invest 2005; 28: 32–36.

105. Toogood A. Safety and efficacy of growth hormone replacement therapy in adults. Expert Opin Drug Saf 2005; 4: 1069–1082.

106. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905–916.

107. Briot K, Tremollieres F, Thomas T, Roux C. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007; 74: 24–31.

108. Bodenner D, Redman C, Riggs A. Teriparatide in the management of osteoporosis. Clin Interv Aging 2007; 2: 499–507.